Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06111508 · ClinicalTrials.gov registry record · NA

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

A NA study of Type 2 Diabetes, sponsored by University of Virginia.

Completed
Registry status
NA
Development phase
30
Enrollment target
2
Study locations

NCT06111508 is a NA study of Type 2 Diabetes that has completed, run by University of Virginia. The registered enrollment target is 30 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06111508, a NA study of Type 2 Diabetes, has completed, sponsored by University of Virginia.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to compare the effect of a continuous glucose monitor (CGM) based titration algorithm to standard titration by self-monitoring blood glucose (SMBG) in participants with Type 2 Diabetes already using long acting insulin. The comparison aims to study the difference in glycemic control between the two therapies. Participants will be followed for 18 weeks and will be provided with Degludec insulin, insulin pen, and a CGM (Dexcom G6).

Conditions Studied

Type 2 Diabetes

Interventions

  • DEVICE Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs

Study Locations (2)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-11-29
Est. Completion 2024-09-16
Phase NA

Sponsor

University of Virginia

449 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06111508

The ClinicalTrials.gov registry entry for NCT06111508 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs is the first listed.

NCT06111508 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Virginia.

Frequently Asked Questions

What is clinical trial NCT06111508 about?

NCT06111508 is a clinical study titled "The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.". The goal of this clinical trial is to compare the effect of a continuous glucose monitor (CGM) based titration algorithm to standard titration by self-monitoring blood glucose (SMBG) in participants with Type 2 Diabetes already using long acting insulin. The comparison aims to study the difference i...

What is the current status of trial NCT06111508?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-11-29. Estimated completion is 2024-09-16.

What conditions does trial NCT06111508 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT06111508?

The interventions under investigation include: Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs (DEVICE).

Who is sponsoring clinical trial NCT06111508?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06111508 being conducted?

This trial has 2 study locations across New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.